Related Experiment Video
Updated: Sep 11, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Antidepressant use in dementia: Assessing effective strategies for a vulnerable population
Mariagiovanna Cozza1, Filippo Luca Fimognari2, Alberto Castagna3
1UOC Intermediate-Long Term Care Budrio Hospital, Integration Department, Italy.
None:
Depression is closely associated with dementia and may serve as a risk factor, an early symptom, or a prodromal feature, particularly in Alzheimer's disease, the most common form of dementia. It can also emerge during disease progression, not only in Alzheimer's but in other dementias such as vascular dementia, Lewy body dementia, and frontotemporal dementia. Recognizing the timing and context of depressive symptoms is crucial for accurate diagnosis and management. While non-pharmacological interventions and psychosocial approaches are generally recommended as the first line of treatment, clinical practice often sees widespread use of antidepressants in this vulnerable population. However, such usage is not always supported by robust evidence, particularly given the heightened risk of side effects in older adults with cognitive decline. This narrative review seeks to critically examine the role of antidepressants in managing depression among patients with dementia. Rather than dismissing their use outright, we aim to provide a novel perspective on their application, emphasizing the importance of a thorough multidimensional geriatric assessment. The attempt is to help the clinicians in making more individualized, evidence-based decisions that balance the potential benefits and risks, ensuring that treatment is tailored to the unique needs of each patient.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Alzheimer's Disease: Treatment
Antidepressant Drugs: Overview
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

